Johnson & Johnson's coronavirus vaccine ready for human trials after proving effective in monkeys

Johnson & Johnson's coronavirus vaccine is showing signs of offering protection in a single dose.
The company has been testing several vaccine contenders on monkeys, and discovered its most effective vaccine produce an immune response and appeared safe in all of them, according to a study published Thursday in the scientific journal Nature. The company will now test the vaccine on humans to determine if it's safe and effective for widespread use.
Johnson & Johnson tested what turned out to be its most viable vaccine on six monkeys, and all of them remained completely safe from lung disease when exposed to the virus. Five of the six remained entirely safe from coronavirus infection when exposed as well. "This gives us confidence that we can test a single-shot vaccine in this epidemic and learn whether it has a protective effect in humans,” Johnson & Johnson's chief scientific officer Dr. Paul Stoffels told Reuters.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
This is the second vaccine proven to be effective in monkeys, Angela Rasmussen, a virologist at Columbia University, noted to The New York Times. But "we can't take shortcuts" and rush into large-scale human trials just because of these results, she cautioned. More than 30 potential COVID-19 vaccines are now undergoing human trials worldwide, though Johnson & Johnson's is one of the few that may only require a single dose and not a follow-up booster shot.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kathryn is a graduate of Syracuse University, with degrees in magazine journalism and information technology, along with hours to earn another degree after working at SU's independent paper The Daily Orange. She's currently recovering from a horse addiction while living in New York City, and likes to share her extremely dry sense of humor on Twitter.
-
US foodies brace for tariff war
Under The Radar Shoppers stocking up on imported olive oil, maple syrup and European wine as price hikes loom
By Chas Newkey-Burden, The Week UK Published
-
How Canadian tariffs could impact tourism to the US
In the Spotlight Canadians represent the largest group of foreign visitors to the United States. But they may soon stop visiting.
By Justin Klawans, The Week US Published
-
Entitlements: DOGE goes after Social Security
Feature Elon Musk is pushing false claims about Social Security fraud
By The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published